Analyst Ratings For Faron Pharmaceuticals Oy (LON:FARN)
Today, Panmure Gordon raised its price target on Faron Pharmaceuticals Oy (LON:FARN) to GBX 404 per share.
There are 1 buy rating on the stock.
The current consensus rating on Faron Pharmaceuticals Oy (LON:FARN) is Buy (Score: 3.00) with a consensus target price of GBX 404 per share, a potential .
Some recent analyst ratings include
- 1/4/2016-RX Securities initiated coverage with a Buy rating.
About Faron Pharmaceuticals Oy (LON:FARN)
Faron Pharmaceuticals Oy is a Finland-based biopharmaceutical company engaged in the biotechnology and medical research industry. The Company develops late stage clinical drugs focusing on acute organ traumas, cancer immunotherapy and vascular damage. Its product pipeline includes Traumakine (FP-1201-lyo), an Acute Respiratory Distress Syndrome (ARDS) treatment that is in phase Three development; and Clevegen (FP-1304), an anti-Clever-1 immunotheraphy tumor targeting candidate that is in pre-clinical stage development.
Recent Trading Activity for Faron Pharmaceuticals Oy (LON:FARN)
Shares of Faron Pharmaceuticals Oy closed the previous trading session at 349.50 up +2.00 0.58% with 0 shares trading hands.
